Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Nivolumab After Cyclophosphamide and Doxorubicin(CA) Induction Therapy in Previously Treated Advanced Non-squamous Cell Non-small Cell Lung Cancer With PD-L1<10%

Next Previous
Search
Trial Profile

Nivolumab After Cyclophosphamide and Doxorubicin(CA) Induction Therapy in Previously Treated Advanced Non-squamous Cell Non-small Cell Lung Cancer With PD-L1<10%

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 03 Apr 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nivolumab (Primary) ; Cyclophosphamide; Doxorubicin
  • Indications Adenocarcinoma; Non-small cell lung cancer
  • Focus Therapeutic Use

    • Most Recent Events

    • 13 Apr 2022 Primary (objective response) endpoint has not been met according to the results presented at the 113th Annual Meeting of the American Association for Cancer Research
    • 13 Apr 2022 Results assessing the efficacy of CA induction therapy to modulate the antitumor effect of the nivolumab in advanced NSCLC presented at the 113th Annual Meeting of the American Association for Cancer Research
    • 20 Mar 2019 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top